Legal Opinion
Altaire Pharmaceuticals, Inc. v. Paragon Bioteck, Inc.
Court of Appeals for the Federal Circuit
Decided May 2, 2018No. 2017-1487PublishedCited by 8 opinions
1Opinion of the Court
Dissenting opinion filed by Circuit Judge Schall.
Wallach, Circuit Judge.
Appellant Altaire Pharmaceuticals, Inc. ("Altaire") sought post-grant review of claims 1-13 ("the Asserted Claims") of Appellee Paragon Bioteck, Inc.'s ("Paragon") U.S. Patent No. 8,859,623 ("the '623 patent"). The U.S. Patent and Trademark Office's Patent Trial and Appeal Board ("PTAB") issued a final written decision determining that Altaire failed to prove that the Asserted Claims were unpatentable for obviousness over two production lots of Altaire's phenylephrine hydrochloride ophthalmic solution products, Lots…
2Cases cited17 opinions
- Lujan v. Defenders of WildlifeSupreme Court of the United States · 1992
- Spokeo, Inc. v. RobinsSupreme Court of the United States · 2016
- DaimlerChrysler Corp. v. CunoSupreme Court of the United States · 2006
- Graver Tank & Mfg. Co. v. Linde Air Products Co.Supreme Court of the United States · 1950
- Texas v. United StatesSupreme Court of the United States · 1998
12 more not listed; retrieve them via the Exa API.
3Cited by8 opinions
- Jtekt Corporation v. Gkn Automotive Ltd.Court of Appeals for the Federal Circuit · 2018
- Avx Corporation v. Presidio Components, Inc.Court of Appeals for the Federal Circuit · 2019
- Momenta Pharmaceuticals, Inc. v. Bristol-Myers Squibb CompanyCourt of Appeals for the Federal Circuit · 2019
- Argentum Pharmaceuticals LLC v. Novartis Pharmaceuticals Corp.Court of Appeals for the Federal Circuit · 2020
- Apple Inc. v. Qualcomm IncorporatedCourt of Appeals for the Federal Circuit · 2021
3 more not listed; retrieve them via the Exa API.